Susana N. Banerjee, MBBS, PhD, on Ovarian Cancer: Novel Combination Therapy Under Study

October 19, 2021 By The ASCO Post Staff

Susana N. Banerjee, MBBS, PhD, of The Royal Marsden NHS Foundation Trust, discusses phase I results that have generated interest in the combination of the RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib for patients with recurrent low-grade serous ovarian cancer, a disease that typically has limited response to conventional chemotherapy and hormonal therapy. The data support ongoing investigation (Abstract 725MO).

Related Content